Costo-utilidad de la vacuna contra el virus de papiloma humano en mujeres peruanas

Alfonso Gutiérrez-Aguado

doi:10.17843/rpmesp.2011.283.518

Authors

Alfonso Gutiérrez-Aguado Facultad de Ciencias Médicas, Universidad César Vallejo-Lima Norte. Lima, Perú. Unidad de Análisis y Generación de Evidencias en Salud Pública, Centro Nacional de Salud Pública, Instituto Nacional de Salud. Lima, Perú. Médico, Especialista de Gestión en salud.

DOI:

https://doi.org/10.17843/rpmesp.2011.283.518

Keywords:

Papillomavirus vaccines, Uterine cervical neoplasms, Inmunization, Costs and cost analysis

Abstract

Objetives. To estimate the cost-utility of the vaccine against the Human Papiloma Virus (HPV) in peruvian women after the application of the vaccine at 10 years of age. Materials and methods. A cost-utility analysis was performed using the Markov´s hidden model in a hypothetical cohort of peruvian women, based on the information on epidemiological parameters, costs associated to uterine cervical cancer (UCC) and the efficacy and costs of the vaccine against the HPV. The vaccination costs were estimated from the Peruvian Ministry of Health perspective and were compared against the quality-adjusted life years (QALYs), using a discount rate of 5%. Results. The annual cost of the vaccination was USD 16’861,490, for the Papanicoau screening it was USD 3’060,793 and the costs associated to the UCC were USD 15’580,000. The incremental cost utility ratio (ICUR) was 6,775 USD/QALY. Conclusions. Vaccination against HPV can be cost-utility compared to not vaccinating.